Memorial Sloan Kettering Cancer Center
The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).
Inclusion Criteria: 1. Patients with relapsed or refractory multiple myeloma who have been treated with a proteasome inhibitor, an IMiD, and an anti-CD38 antibody. Patients who have been treated with at least 2 prior lines of therapy are eligible. Multiple myeloma is defined by the International Myeloma Working Group (IMWG) updated criteria. 2. Patients need to have measurable disease defined by one or more of the following: 1. Serum myeloma (M)-protein greater than or equal to 0.5 g/dL (5 g/L). 2. Urine M-protein greater or equal to 200 mg/24 h. 3. Involved light chain (either kapp…
After the priming, patients will start Teclistamab step up dosing. Mezigdomide will not be given during the Teclistamab step up. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.
Start with 14 days of Mezigdomide. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.